Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol
- Development stage
- Unknown
- Lead developer
- Collaborations Pharmaceuticals
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule with the molecular formula C24H29ClN6OS and a molecular weight of approximately 485 g/mol. It contains a triazine core substituted with piperazine and phenolic groups as well as a chlorinated aromatic side chain. The compound is listed in chemical databases such as DrugBank (DB04020), PubChem (CID: 9957008), and ChEMBL (CHEMBL346455). It is classified as an experimental or research molecule rather than an approved pharmaceutical agent. There are no publicly available data on its clinical use or mechanism of action in humans. Its structure suggests potential for activity at protein targets relevant to medicinal chemistry but no specific pharmacological profile or indication has been established.[1][2][5]
- Other names
- 4-(2-{[4-{[3-(4-chlorophenyl)propyl]sulfanyl}-6-(1-piperazinyl)-1,3,5-triazin-2-yl]amino}ethyl)phenol4-(2-((4-((3-(4-chlorophenyl)propyl)sulfanyl)-6-(piperazin-1-yl)-1,3,5-triazin-2-yl)amino)ethyl)phenol4-{2-[(4-{[3-(4-chlorophenyl)propyl]sulfanyl}-6-(piperazin-1-yl)-1,3,5-triazin-2 yl)amino]ethyl}phenol
Beyond the preview
Go deeper on 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol.